TALPHERA Reports Material Agreement, Equity Sales, Financial Condition

TL;DR

**TALPHERA just sold new shares and made a big deal, watch for dilution and strategic shifts.**

AI Summary

TALPHERA, INC. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K on January 22, 2024, reporting events from January 17, 2024. This filing indicates the company entered into a material definitive agreement, discussed results of operations and financial condition, and reported unregistered sales of equity securities. This matters to investors because these actions, particularly the sale of equity, could dilute existing shares and impact the stock's value, while the material agreement and financial condition updates are crucial for assessing the company's future prospects.

Why It Matters

The entry into a material definitive agreement and unregistered sales of equity securities can significantly impact TALPHERA's financial structure and future operations, potentially affecting shareholder value through dilution or new strategic directions.

Risk Assessment

Risk Level: medium — The unregistered sale of equity securities can lead to dilution for existing shareholders, and the details of the material definitive agreement are not yet public, creating uncertainty.

Analyst Insight

A smart investor would closely monitor subsequent filings for details on the 'Material Definitive Agreement' and the terms of the 'Unregistered Sales of Equity Securities' to assess potential dilution and strategic implications before making investment decisions.

Key Players & Entities

• TALPHERA, INC. (company) — the registrant filing the 8-K
• AcelRx Pharmaceuticals Inc. (company) — former name of TALPHERA, INC.
• January 17, 2024 (date) — date of earliest event reported
• January 22, 2024 (date) — filing date of the 8-K

Forward-Looking Statements

• TALPHERA's stock price will experience short-term volatility due to the unregistered sales of equity securities. (TALPHERA, INC.) — medium confidence, target: Q1 2024
• Further details regarding the 'Material Definitive Agreement' will be disclosed in subsequent filings or press releases. (TALPHERA, INC.) — high confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar
• $0.769 — "Common Stock"), at a purchase price of $0.769 per share and an exercise price of $0.0
• $6.0 million — roceeds to the Company of approximately $6.0 million excluding the proceeds, if any, from th
• $0.92 — f its pivotal trial data being at least $0.92 per share (the "Price Milestone"), whic
• $10.0 million — roceeds to the Company of approximately $10.0 million with respect to the Pivotal Trial Miles
• $2.0 million — pect to the Pivotal Trial Milestone and $2.0 million with respect to the Price Milestone, ex
• $0.77 — reduce the exercise price thereunder to $0.77 per share.       &#x
• $9.4 million — December 31, 2023 totaled approximately $9.4 million. The full text of the press release is

Filing Documents

• acrx20240117c_8k.htm (8-K) — 44KB
• ex_616384.htm (EX-10.1) — 240KB
• ex_616385.htm (EX-10.2) — 227KB
• ex_616386.htm (EX-10.3) — 168KB
• ex_616387.htm (EX-10.4) — 95KB
• ex_616388.htm (EX-99.1) — 26KB
• ex_616388img001.jpg (GRAPHIC) — 4KB
• 0001437749-24-001879.txt ( ) — 1110KB
• tlph-20240117.xsd (EX-101.SCH) — 3KB
• tlph-20240117_def.xml (EX-101.DEF) — 11KB
• tlph-20240117_lab.xml (EX-101.LAB) — 15KB
• tlph-20240117_pre.xml (EX-101.PRE) — 11KB
• acrx20240117c_8k_htm.xml (XML) — 2KB

02

Item 2.02 Results of Operations and Financial Condition.   On January 18, 2024, the Company issued a press release reporting that its preliminary cash balance as of December 31, 2023 totaled approximately $9.4 million. The full text of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.   The information contained in this Item 2.02 and in Exhibit 99.1 shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.  

02

Item 3.02 Unregistered Sales of Equity Securities.   The information contained above in Item 1.01 relating to the Private Placement is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of the Purchasers in the Securities Purchase Agreements, the offering and sale of the securities described above are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws.   Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.  

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   Pursuant to terms of the Securities Purchase Agreements with entities affiliated with Nantahala Management, LLC and effective upon the first closing of the Private Placement, which occurred on January 22, 2024, the board of directors of the Company appointed Abhinav Jain to serve as a Class II Director to hold office for the balance of a term expiring at the Company's 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal.   Mr. Jain will participate in the Company's non-employee director compensation program, as described in the Company's proxy statement for the 2023 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on August 28, 2023, as may be adjusted by the board of directors of the Company from time to time.  Additionally, the Company intends to enter into a non-employee director indemnification agreement with Mr. Jain.   There are no family relationships between Mr. Jain and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K, other than the transactions contemplated by the Private Placement.  

01

Item 7.01 Regulation FD Disclosure.   On January 18, 2024, the Company issued a press release announcing the Private Placement. The full text of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.   The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section and shall not deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.   Item  9.01

Financial Statements and Exhibits

Financial Statements and Exhibits.   (d) Exhibits   Exhibit No. Description 10.1 Form of Securities Purchase Agreement, dated January 17, 2024, by and among Talphera, Inc. and entities affiliated with Nantahala Management, LLC. 10.2 Form of Securities Purchase Agreement, dated January 17, 2024 by and among Talphera, Inc. and Investor Company ITF Rosalind Master Fund L.P. 10.3 Form of Registration Rights Agreement, dated January 17, 2024, by and among Talphera, Inc. and the Purchasers. 10.4 Form of Pre-Funded Warrant (January 2024). 99.1 Press Release, dated January 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Date: January 22, 2024 TALPHERA, INC.        By:   /s/ Raffi Asadorian       Raffi Asadorian       Chief Financial Officer        

View Full Filing

View this 8-K filing on SEC EDGAR